X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs BIOCON LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA BIOCON LTD TORRENT PHARMA/
BIOCON LTD
 
P/E (TTM) x 48.1 51.4 93.5% View Chart
P/BV x 6.5 7.5 87.2% View Chart
Dividend Yield % 0.8 0.2 507.4%  

Financials

 TORRENT PHARMA   BIOCON LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
BIOCON LTD
Mar-18
TORRENT PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,188 130.5%   
Low Rs1,144305 374.9%   
Sales per share (Unadj.) Rs354.768.7 516.1%  
Earnings per share (Unadj.) Rs40.17.6 530.7%  
Cash flow per share (Unadj.) Rs64.214.0 459.7%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %1.00.1 776.0%  
Book value per share (Unadj.) Rs273.186.3 316.3%  
Shares outstanding (eoy) m169.22600.00 28.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.810.9 35.0%   
Avg P/E ratio x33.698.9 34.0%  
P/CF ratio (eoy) x21.053.4 39.2%  
Price / Book Value ratio x4.98.6 57.0%  
Dividend payout %34.913.2 263.8%   
Avg Mkt Cap Rs m227,897447,900 50.9%   
No. of employees `00014.76.1 239.1%   
Total wages/salary Rs m11,3539,311 121.9%   
Avg. sales/employee Rs Th4,083.06,705.8 60.9%   
Avg. wages/employee Rs Th772.31,514.2 51.0%   
Avg. net profit/employee Rs Th461.3736.9 62.6%   
INCOME DATA
Net Sales Rs m60,02141,234 145.6%  
Other income Rs m2,9882,062 144.9%   
Total revenues Rs m63,00943,296 145.5%   
Gross profit Rs m13,4938,291 162.7%  
Depreciation Rs m4,0863,851 106.1%   
Interest Rs m3,085615 501.6%   
Profit before tax Rs m9,3105,887 158.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,569 161.2%   
Profit after tax Rs m6,7814,531 149.7%  
Gross profit margin %22.520.1 111.8%  
Effective tax rate %27.226.7 101.9%   
Net profit margin %11.311.0 102.8%  
BALANCE SHEET DATA
Current assets Rs m52,62341,486 126.8%   
Current liabilities Rs m52,02221,413 242.9%   
Net working cap to sales %1.048.7 2.1%  
Current ratio x1.01.9 52.2%  
Inventory Days Days12064 187.0%  
Debtors Days Days7694 80.9%  
Net fixed assets Rs m85,01650,661 167.8%   
Share capital Rs m8463,000 28.2%   
"Free" reserves Rs m45,37648,808 93.0%   
Net worth Rs m46,22251,808 89.2%   
Long term debt Rs m41,11517,898 229.7%   
Total assets Rs m142,43299,897 142.6%  
Interest coverage x4.010.6 38.0%   
Debt to equity ratio x0.90.3 257.5%  
Sales to assets ratio x0.40.4 102.1%   
Return on assets %6.95.2 134.5%  
Return on equity %14.78.7 167.8%  
Return on capital %14.29.6 147.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58012,058 120.9%   
Fx outflow Rs m3,6007,348 49.0%   
Net fx Rs m10,9804,710 233.1%   
CASH FLOW
From Operations Rs m8,9426,621 135.1%  
From Investments Rs m-47,070-6,840 688.2%  
From Financial Activity Rs m34,174-2,397 -1,425.7%  
Net Cashflow Rs m-3,655-2,612 139.9%  

Share Holding

Indian Promoters % 71.5 40.4 177.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.0 8.4 83.6%  
FIIs % 12.6 10.7 117.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.9 44.2%  
Shareholders   26,511 109,995 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  STERLING BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS